13 February 2025 - After nearly two years of stalled discussions, the Keytruda (pembrolizumab) reimbursement expansion debate has finally begun. ...
12 February 2025 - Gozetotide binds to the cancer cells with prostate-specific membrane antigen on their surface, making them visible during ...
12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of ...
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
12 February 2025 - Izervay dosing approved beyond 12 months. ...
12 February 2025 - On 11 February 2025, the FDA approved brentuximab vedotin (Adcetris, Seagen) in combination with lenalidomide and a ...
12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of ...
11 February 2025 - Approval is based on the Phase 3 KEYNOTE-671 trial. ...
11 February 2025 - Approval based on positive results from Phase 3 ATTRibute-CM study. ...
11 February 2025 - Today, the FDA approved mirdametinib (Gomekli, SpringWorks Therapeutics), a kinase inhibitor, for adult and paediatric patients ...
7 February 2025 - Gilead's triple negative breast cancer treatment Trodelvy (trastuzumab govitecan) had surmounted a significant hurdle for health ...
10 February 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
7 February 2025 - Emblaveo is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the US FDA to ...
21 January 2025 - Today, the FDA approved treosulfan (Grafapex, medac), an alkylating agent, with fludarabine as a preparative regimen ...